NICE updates guidance and extends use of omalizumab in severe allergic asthma

Omalizumab (Xolair) has been accepted by NICE for broader use in the treatment of severe persistent immunoglobulin E (IgE)-mediated asthma.

Previously treatment with omalizumab could only be initiated on the NHS if the patient had severe exacerbations which required hospital admission (pictured) | SCIENCE PHOTO LIBRARY
Previously treatment with omalizumab could only be initiated on the NHS if the patient had severe exacerbations which required hospital admission (pictured) | SCIENCE PHOTO LIBRARY

It can now be used on the NHS for adults and children from 6 years of age who need continuous or frequent treatment with oral corticosteroids (≥4 courses in the previous year), provided the manufacturer supplies it with the discount agreed in the patient access scheme.

Omalizumab must be used as an add-on to optimised standard therapy, defined as a full trial of (and, if tolerated, documented compliance with) inhaled high-dose corticosteroids, long-acting ß2-agonists, leukotriene receptor antagonists, theophylline, oral corticosteroids and smoking cessation if clinically appropriate.

In its assessment, NICE noted the ‘life-changing’ effect of omalizumab reported by patients and concluded that omalizumab as an add-on to optimised standard therapy is more clinically effective in treating severe persistent allergic asthma than optimised standard therapy alone, leading to a reduction in total emergency visits (including hospital admissions, A&E visits and unscheduled GP visits) in adults, reduced hospital admissions in children, improved lung function in adults and a reduction in the frequency and use of rescue medication and oral corticosteroids.

View Xolair drug record

NICE guidance on omalizumab

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more